Analytical Data
-
基因名
CD39 / ENTPD1
- Application
-
别名
CD39 / ENTPD1；
-
种属
Human
-
表达系统
E. coli
-
标签
His tag N-Terminus
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
P49961
-
表达区间
1-510aa
-
氨基酸序列
MEDTKESNVKTFCSKNILAILGFSSIIAVIALLAVGLTQNKALPENVKYG IVLDAGSSHTSLYIYKWPAEKENDTGVVHQVEECRVKGPGISKFVQKVNE IGIYLTDCMERAREVIPRSQHQETPVYLGATAGMRLLRMESEELADRVLD VVERSLSNYPFDFQGARIITGQEEGAYGWITINYLLGKFSQKTRWFSIVP YETNNQETFGALDLGGASTQVTFVPQNQTIESPDNALQFRLYGKDYNVYT HSFLCYGKDQALWQKLAKDIQVASNEILRDPCFHPGYKKVVNVSDLYKTP CTKRFEMTLPFQQFEIQGIGNYQQCHQSILELFNTSYCPYSQCAFNGIFL PPLQGDFGAFSAFYFVMKFLNLTSEKVSQEKVTEMMKKFCAQPWEEIKTS YAGVKEKYLSEYCFSGTYILSLLLQGYHFTADSWEHIHFIGKIQGSDAGW TLGYMLNLTNMIPAEQPLSTPLSHSTYVFLMVLFSLVLFTVAIIGLLIFH KPSYFWKDMV
-
分子量
82 kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
CD39, also known as ENTPD1, is an ecto-nucleotide triphosphate diphosphohydrolase that plays a crucial role in regulating the immune response and maintaining tissue homeostasis. This enzyme catalyzes the hydrolysis of extracellular ATP and ADP, thereby modulating purinergic signaling, which is essential for various physiological processes. Elevated levels of ATP in the tumor microenvironment can promote inflammation and immune suppression, while CD39 helps to mitigate these effects by depleting ATP. As such, CD39 has gained significant attention in cancer immunotherapy as a potential target for enhancing antitumor immunity. The development of recombinant CD39 proteins enables researchers to conduct in-depth studies regarding its enzymatic functions, substrate specificity, and interactions with other immune modulatory pathways. Additionally, understanding CD39's role in different pathological conditions, including cancer, autoimmune diseases, and chronic inflammatory disorders, is critical for devising novel therapeutic strategies. By generating recombinant CD39 proteins, scientists aim to elucidate the molecular mechanisms underlying CD39-mediated immune regulation and explore their potential for therapeutic intervention, making it a focal point of contemporary biomedical research.
